Court Lifts Preliminary Injunction for Alleged Imminent Infringement of Patent

摘要

Astrazeneca, along with its Spanish subsidiary Astrazen-eca Farmaceutica Spain SA and Laboratorio Beta, SA, had filed an ex parte preliminary injunction petition against Sandoz Farmaceutica, SA for the alleged imminent infringement of European patent EP1020461, validated in Spain as ES2326405, which claims a magnesium salt of esomeprazole with an optical purity of 99.8% en-antiomeric excess (ee) and its use for the treatment of gastric diseases.rnEsomeprazole is one of the enantiomers of omeprazole, which is a racemic compound commercialized since the 1980s as a gastric acid inhibitor.